Last checked at 17 Dec 2021 15:38
Renalytix plc
("Renalytix" or the "Company")
Result of AGM
LONDON and SALT LAKE, 17 December 2021 - Renalytix (NASDAQ: RNLX) (LSE: RENX) announces that at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
The results of the AGM are detailed below:
Resolution | In Favour | Against | Withheld | ||||
Votes | % | Votes | % | Votes | |||
1 | 36,309,096 | 99.95% | 16,442 | 0.05% | 40,498 | ||
2 | 25,272,488 | 70.34% | 10,658,539 | 29.66% | 26,932 | ||
3 | 27,437,320 | 76.36% | 8,493,707 | 23.64% | 26,932 | ||
4 | 36,289,799 | 99.81% | 67,343 | 0.19% | 8,894 | ||
5 | 36,339,057 | 99.95% | 18,085 | 0.05% | 8,894 | ||
6 | 36,337,208 | 99.95% | 16,694 | 0.05% | 12,134 | ||
7 | 36,339,655 | 99.95% | 17,268 | 0.05% | 9,113 | ||
8 | 35,826,173 | 98.54% | 529,873 | 1.46% | 9,990 | ||
9 | 27,776,213 | 77.27% | 8,170,453 | 22.73% | 11,293 | ||
10 | 35,891,613 | 99.94% | 21,157 | 0.06% | 45,189 |
For further information, please contact:
Renalytix plc | www.renalytix.com | |
James McCullough, CEO | Via Walbrook PR | |
Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | |
Alex Price / Nicholas Moore | ||
Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 | |
Gary Clarence / Daniel Adams | ||
Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | |
Paul McManus / Lianne Applegarth | Mob: 07980 541 893 / 07584 391 303 | |
About KidneyIntelX
KidneyIntelX is a first-of-kind solution that enables early-stage diabetic kidney disease (DKD) progression risk assessment by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems, and employs a proprietary algorithm to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.